BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study.

MLA

Harter, Philipp, et al. “BRCA1/2 Mutations Associated with Progression-Free Survival in Ovarian Cancer Patients in the AGO-OVAR 16 Study.” Gynecologic Oncology, vol. 140, no. 3, Mar. 2016, pp. 443–49. EBSCOhost, https://doi.org/10.1016/j.ygyno.2015.12.027.

APA

Harter, P., Johnson, T., Berton-Rigaud, D., Park, S.-Y., Friedlander, M., Del Campo, J. M., Shimada, M., Forget, F., Mirza, M. R., Colombo, N., Zamagni, C., Chan, J. K., Imhof, M., Herzog, T. J., O’Donnell, D., Heitz, F., King, K., Stinnett, S., Barrett, C., … du Bois, A. (2016). BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study. Gynecologic Oncology, 140(3), 443–449. https://doi.org/10.1016/j.ygyno.2015.12.027

Chicago

Harter, Philipp, Toby Johnson, Dominique Berton-Rigaud, Sang-Yoon Park, Michael Friedlander, Josep M Del Campo, Muneaki Shimada, et al. 2016. “BRCA1/2 Mutations Associated with Progression-Free Survival in Ovarian Cancer Patients in the AGO-OVAR 16 Study.” Gynecologic Oncology 140 (3): 443–49. doi:10.1016/j.ygyno.2015.12.027.